Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification and characterization of Sofosbuvir-resistant mutations of hepatitis C virus genotype 3a replicon.

Journal of medical virology - 1 Dec 2023

Ngari Jackline Wangu, Leumi Steve, Han Lin, Liu Chaolun, Tong Yimin, Zhong Jin

Abstract excerpt

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide. Among its 8 genotypes (GT), GT3 has a relatively lower sustained virological response to highly effective direct-acting antiviral agents (DAA). Sofosbuvir (SOF), an anti-NS5B polymerase inhibitor, is a core component of many anti-HCV DAA cocktail regimens, and its resistant mutations are rare in clinics because these mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Replicon

Share to Sofosbuvir

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 38102947
DOI: 10.1002/jmv.29290

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification and characterization of Sofosbuvir-resistant mutations of hepatitis C virus genotype 3a replicon.PMID 38102947Read ↗

Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.Semantic proximity Read ↗

Construction and characterization of a new hepatitis C virus genotype 6a subgenomic replicon that is prone to render the sofosbuvir resistance.Semantic proximity Read ↗

Sofosbuvir-based therapies achieved satisfactory virological response in Chinese with genotypes 3 and 6 infection: a real-world experience from a centreSemantic proximity Read ↗

Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: an observational cohort.Semantic proximity Read ↗

Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.Semantic proximity Read ↗

Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb study.Semantic proximity Read ↗

Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems.Semantic proximity Read ↗

Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.Semantic proximity Read ↗

Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.Semantic proximity Read ↗

High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.Semantic proximity Read ↗

Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan.Semantic proximity Read ↗

Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.